Molgramostim

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Pulmonary Alveolar Proteinosis

Conditions

Autoimmune Pulmonary Alveolar Proteinosis

Trial Timeline

Oct 22, 2025 → Dec 1, 2027

About Molgramostim

Molgramostim is a phase 3 stage product being developed by Savara for Autoimmune Pulmonary Alveolar Proteinosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06431776. Target conditions include Autoimmune Pulmonary Alveolar Proteinosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT06431776Phase 3Recruiting
NCT03482752Phase 3Terminated

Competing Products

20 competing products in Autoimmune Pulmonary Alveolar Proteinosis

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
77
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
33
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
33
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
52
Enteric-coated Mycophenolate SodiumNovartisPhase 3
77
Ianalumab + PlaceboNovartisPhase 3
77
VAY736NovartisPhase 2/3
65
remibrutinibNovartisPhase 1
33
RO7049665RochePhase 2
52
rituximab (Mabthera®) + PlaceboRochePhase 3
77
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)Swedish Orphan BiovitrumPhase 2
51
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
51
BMS-986165Bristol Myers SquibbPhase 1
32
NivolumabBristol Myers SquibbPhase 1
32
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
32
BMS-986165 + RosuvastatinBristol Myers SquibbPhase 1
32
SAR445088SanofiPhase 1
32
BIVV020SanofiPhase 1
32
rilzabrutinibSanofiPhase 2
51